MADRIGAL PHARMACEUTICALS, INC. Impairment of Long-Lived Assets Held-for-use
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2016-03-15
- MADRIGAL PHARMACEUTICALS, INC. impairment of long-lived assets held-for-use for fiscal 2015 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. impairment of long-lived assets held-for-use for fiscal 2014 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. impairment of long-lived assets held-for-use for fiscal 2013 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. impairment of long-lived assets held-for-use for fiscal 2012 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|
| 2015-12-31 | $0.00 10-K · filed 2016-03-15 |
| 2014-12-31 | $0.00 10-K · filed 2016-03-15 |
| 2013-12-31 | $0.00 10-K · filed 2015-03-12 |
| 2012-12-31 | $0.00 10-K · filed 2014-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |